{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,11,5]],"date-time":"2026-11-05T09:42:30Z","timestamp":1793871750071,"version":"4.6.1"},"reference-count":88,"publisher":"The Endocrine Society","issue":"3","license":[{"start":{"date-parts":[[2022,12,21]],"date-time":"2022-12-21T00:00:00Z","timestamp":1671580800000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/academic.oup.com\/pages\/standard-publication-reuse-rights"}],"funder":[{"DOI":"10.13039\/100005709","name":"Endocrine Society","doi-asserted-by":"crossref","id":[{"id":"10.13039\/100005709","id-type":"DOI","asserted-by":"crossref"}]}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":[],"published-print":{"date-parts":[[2023,2,15]]},"abstract":"<jats:title>Abstract<\/jats:title>\n                  <jats:sec>\n                    <jats:title>Background<\/jats:title>\n                    <jats:p>Hypercalcemia of malignancy (HCM) is the most common metabolic complication of malignancies, but its incidence may be declining due to potent chemotherapeutic agents. The high mortality associated with HCM has declined markedly due to the introduction of increasingly effective chemotherapeutic drugs. Despite the widespread availability of efficacious medications to treat HCM, evidence-based recommendations to manage this debilitating condition are lacking.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Objective<\/jats:title>\n                    <jats:p>To develop guidelines for the treatment of adults with HCM.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Methods<\/jats:title>\n                    <jats:p>A multidisciplinary panel of clinical experts, together with experts in systematic literature review, identified and prioritized 8 clinical questions related to the treatment of HCM in adult patients. The systematic reviews (SRs) queried electronic databases for studies relevant to the selected questions. The Grading of Recommendations Assessment, Development and Evaluation (GRADE) methodology was used to assess the certainty of evidence and make recommendations. An independent SR was conducted in parallel to assess patients' and physicians' values and preferences, costs, resources needed, acceptability, feasibility, equity, and other domains relevant to the Evidence-to-Decision framework as well as to enable judgements and recommendations.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Results<\/jats:title>\n                    <jats:p>The panel recommends (strong recommendation) in adults with HCM treatment with denosumab (Dmab) or an intravenous (IV) bisphosphonate (BP). The following recommendations were based on low certainty of the evidence. The panel suggests (conditional recommendation) (1) in adults with HCM, the use of Dmab rather than an IV BP; (2) in adults with severe HCM, a combination of calcitonin and an IV BP or Dmab therapy as initial treatment; and (3) in adults with refractory\/recurrent HCM despite treatment with BP, the use of Dmab. The panel suggests (conditional recommendation) the addition of an IV BP or Dmab in adult patients with hypercalcemia due to tumors associated with high calcitriol levels who are already receiving glucocorticoid therapy but continue to have severe or symptomatic HCM. The panel suggests (conditional recommendation) in adult patients with hypercalcemia due to parathyroid carcinoma, treatment with either a calcimimetic or an antiresorptive (IV BP or Dmab). The panel judges the treatments as probably accessible and feasible for most recommendations but noted variability in costs, resources required, and their impact on equity.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Conclusions<\/jats:title>\n                    <jats:p>The panel's recommendations are based on currently available evidence considering the most important outcomes in HCM to patients and key stakeholders. Treatment of the primary malignancy is instrumental for controlling hypercalcemia and preventing its recurrence. The recommendations provide a framework for the medical management of adults with HCM and incorporate important decisional and contextual factors. The guidelines underscore current knowledge gaps that can be used to establish future research agendas.<\/jats:p>\n                  <\/jats:sec>","DOI":"10.1210\/clinem\/dgac621","type":"journal-article","created":{"date-parts":[[2022,12,22]],"date-time":"2022-12-22T02:44:32Z","timestamp":1671677072000},"page":"507-528","source":"Crossref","is-referenced-by-count":117,"title":["Treatment of Hypercalcemia of Malignancy in Adults: An Endocrine Society Clinical Practice Guideline"],"prefix":"10.1210","volume":"108","author":[{"ORCID":"https:\/\/orcid.org\/0000-0002-2076-5858","authenticated-orcid":false,"given":"Ghada","family":"El-Hajj Fuleihan","sequence":"first","affiliation":[{"name":"Department of Internal Medicine, American University of Beirut , Beirut 11 0236 , Lebanon"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-3755-7529","authenticated-orcid":false,"given":"Gregory A","family":"Clines","sequence":"additional","affiliation":[{"name":"Department of Internal Medicine, University of Michigan , Ann Arbor, MI 48109 , USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-0355-030X","authenticated-orcid":false,"given":"Mimi I","family":"Hu","sequence":"additional","affiliation":[{"name":"Department of Endocrine Neoplasia and Hormonal Disorders, University of Texas M. D. Anderson Cancer Center , Houston, TX 77030 , USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-6568-8588","authenticated-orcid":false,"given":"Claudio","family":"Marcocci","sequence":"additional","affiliation":[{"name":"Department of Clinical and Experimental Medicine, University of Pisa , Pisa 56100 , Italy"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-5502-5975","authenticated-orcid":false,"given":"M Hassan","family":"Murad","sequence":"additional","affiliation":[{"name":"Evidence-based Practice Center, Mayo Clinic , Rochester, MN 55905 , USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-1643-5386","authenticated-orcid":false,"given":"Thomas","family":"Piggott","sequence":"additional","affiliation":[{"name":"Department of Health Research Methods, Evidence and Impact, McMaster University , Hamilton, ON, L8S 4K1 , Canada"},{"name":"MacGRADE Centre, McMaster University , Hamilton, ON, L8S 4K1 , Canada"},{"name":"Department of Family Medicine, Queens University , Kingston, ON, K7L 3G2 , Canada"},{"name":"Peterborough Public Health , Peterborough, ON, K9J 2R8 , Canada"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-5523-6908","authenticated-orcid":false,"given":"Catherine","family":"Van Poznak","sequence":"additional","affiliation":[{"name":"Department of Internal Medicine, University of Michigan , Ann Arbor, MI 48109 , USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-1897-4503","authenticated-orcid":false,"given":"Joy Y","family":"Wu","sequence":"additional","affiliation":[{"name":"Department of Medicine, Stanford University School of Medicine , Stanford, CA 94305 , USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-3662-7345","authenticated-orcid":false,"given":"Matthew T","family":"Drake","sequence":"additional","affiliation":[{"name":"Department of Internal Medicine, Mayo Clinic , Rochester, MN 55905 , USA"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"80","published-online":{"date-parts":[[2022,12,21]]},"reference":[{"issue":"4","key":"2023033115541091900_","doi-asserted-by":"crossref","first-page":"373","DOI":"10.1056\/NEJMcp042806","article-title":"Clinical practice. Hypercalcemia associated with cancer","volume":"352","author":"Stewart","year":"2005","journal-title":"N Engl J Med"},{"issue":"23","key":"2023033115541091900_","doi-asserted-by":"crossref","first-page":"3462","DOI":"10.2174\/092986711796642490","article-title":"Malignant hypercalcemia","volume":"18","author":"Basso","year":"2011","journal-title":"Curr Med Chem"},{"issue":"1","key":"2023033115541091900_","doi-asserted-by":"crossref","first-page":"48","DOI":"10.1053\/j.semnephrol.2003.08.015","article-title":"Hypercalcemia of malignancy","volume":"24","author":"Body","year":"2004","journal-title":"Seminars Nephrol"},{"issue":"4","key":"2023033115541091900_","doi-asserted-by":"crossref","first-page":"253","DOI":"10.1023\/A:1026597816193","article-title":"Hypercalcemia of malignancy","volume":"1","author":"Grill","year":"2000","journal-title":"Rev Endocr Metab Disord"},{"issue":"5","key":"2023033115541091900_","first-page":"1551","article-title":"Cancer-induced hypercalcemia","volume":"29","author":"Lumachi","year":"2009","journal-title":"Anticancer Res"},{"issue":"8","key":"2023033115541091900_","doi-asserted-by":"crossref","first-page":"2091","DOI":"10.1002\/cam4.749","article-title":"Prevalence of hypercalcemia among cancer patients in the United States","volume":"5","author":"Gastanaga","year":"2016","journal-title":"Cancer Med"},{"issue":"12","key":"2023033115541091900_","doi-asserted-by":"crossref","first-page":"770","DOI":"10.1055\/a-1049-0647","article-title":"Pathophysiology and management of hypercalcemia in malignancy: a review of the literature","volume":"51","author":"Asonitis","year":"2019","journal-title":"Horm Metab Res"},{"key":"2023033115541091900_","first-page":"176","article-title":"Hypercalcemia: pathogenesis, clinical manifestations, differential diagnosis, and management","author":"Shane","year":"2006","journal-title":"Primer Metab Bone Dis Disorders Mineral Metab"},{"issue":"4","key":"2023033115541091900_","doi-asserted-by":"crossref","first-page":"69","DOI":"10.3810\/pgm.2004.04.1486","article-title":"Understanding hypercalcemia. Its metabolic basis, signs, and symptoms","volume":"115","author":"Inzucchi","year":"2004","journal-title":"Postgrad Med"},{"issue":"5","key":"2023033115541091900_","first-page":"496","article-title":"Hypercalcemia of malignancy","volume":"9","author":"Feldenzer","year":"2018","journal-title":"J Adv Practitioner Oncol"},{"issue":"7","key":"2023033115541091900_","doi-asserted-by":"crossref","first-page":"499","DOI":"10.7326\/0003-4819-112-7-499","article-title":"Cancer-associated hypercalcemia: morbidity and mortality. Clinical experience in 126 treated patients","volume":"112","author":"Ralston","year":"1990","journal-title":"Ann Intern Med"},{"issue":"5","key":"2023033115541091900_","doi-asserted-by":"crossref","first-page":"426","DOI":"10.1200\/JOP.2016.011155","article-title":"Cancer-related hypercalcemia","volume":"12","author":"Goldner","year":"2016","journal-title":"J Oncol Pract"},{"issue":"5","key":"2023033115541091900_","doi-asserted-by":"crossref","first-page":"377","DOI":"10.3322\/caac.21489","article-title":"Hypercalcemia and cancer: differential diagnosis and treatment","volume":"68","author":"Zagzag","year":"2018","journal-title":"CA Cancer J Clin"},{"issue":"4","key":"2023033115541091900_","doi-asserted-by":"crossref","first-page":"259","DOI":"10.7326\/0003-4819-149-4-200808190-00007","article-title":"Narrative review: furosemide for hypercalcemia: an unproven yet common practice","volume":"149","author":"LeGrand","year":"2008","journal-title":"Ann Intern Med"},{"issue":"4","key":"2023033115541091900_","doi-asserted-by":"crossref","first-page":"781","DOI":"10.1016\/j.ecl.2021.08.002","article-title":"Treatment of hypercalcemia of malignancy","volume":"50","author":"Chakhtoura","year":"2021","journal-title":"Endocrinol Metab Clin North Am"},{"issue":"15","key":"2023033115541091900_","doi-asserted-by":"crossref","first-page":"1443","DOI":"10.1056\/NEJMcp2113128","article-title":"Cancer-Associated hypercalcemia","volume":"386","author":"Guise","year":"2022","journal-title":"N Engl J Med"},{"issue":"3","key":"2023033115541091900_","doi-asserted-by":"crossref","DOI":"10.1210\/clinem\/dgac630","article-title":"Patient and physician decisional factors regarding hypercalcemia of malignancy treatment: a novel mixed-methods study","volume":"108","author":"Bassatne","year":"2023","journal-title":"J Clin Endocrinol Metab"},{"key":"2023033115541091900_","author":"Seisa"},{"issue":"8","key":"2023033115541091900_","doi-asserted-by":"crossref","first-page":"331","DOI":"10.3109\/07357907.2015.1047506","article-title":"Quality and outcomes of treatment of hypercalcemia of malignancy","volume":"33","author":"Wright","year":"2015","journal-title":"Cancer Invest"},{"issue":"18","key":"2023033115541091900_","doi-asserted-by":"crossref","first-page":"1417","DOI":"10.1093\/jnci\/djt225","article-title":"Denosumab for patients with persistent or relapsed hypercalcemia of malignancy despite recent bisphosphonate treatment","volume":"105","author":"Hu","year":"2013","journal-title":"J Natl Cancer Inst"},{"issue":"9","key":"2023033115541091900_","doi-asserted-by":"crossref","first-page":"979","DOI":"10.1089\/jpm.2015.0460","article-title":"Interspecialty differences in physicians' attitudes, beliefs, and reasons for withdrawing or withholding hypercalcemia treatment in terminally ill patients","volume":"19","author":"Mori","year":"2016","journal-title":"J Palliative Med"},{"issue":"1","key":"2023033115541091900_","doi-asserted-by":"crossref","first-page":"177","DOI":"10.1007\/s00520-014-2355-4","article-title":"Physicians' attitude toward recurrent hypercalcemia in terminally ill cancer patients","volume":"23","author":"Shimada","year":"2015","journal-title":"Supportive Care Cancer"},{"issue":"1","key":"2023033115541091900_","doi-asserted-by":"crossref","first-page":"96","DOI":"10.1056\/NEJMx220006","article-title":"Cancer-associated hypercalcemia: correction","volume":"387","author":"Guise","year":"2022","journal-title":"N Engl J Med"},{"issue":"6937","key":"2023033115541091900_","doi-asserted-by":"crossref","first-page":"337","DOI":"10.1038\/nature01658","article-title":"Osteoclast differentiation and activation","volume":"423","author":"Boyle","year":"2003","journal-title":"Nature"},{"issue":"7","key":"2023033115541091900_","doi-asserted-by":"crossref","first-page":"1625","DOI":"10.1007\/s00198-022-06369-z","article-title":"Rebound hypercalcemia post-denosumab cessation in metastatic breast cancer","volume":"33","author":"Wang","year":"2022","journal-title":"Osteoporos Int"},{"issue":"6","key":"2023033115541091900_","doi-asserted-by":"crossref","first-page":"1078","DOI":"10.1002\/pbc.25393","article-title":"Critical hypercalcemia following discontinuation of denosumab therapy for metastatic giant cell tumor of bone","volume":"62","author":"Gossai","year":"2015","journal-title":"Pediatric Blood Cancer"},{"issue":"4","key":"2023033115541091900_","doi-asserted-by":"crossref","first-page":"391","DOI":"10.1007\/s00223-022-01002-x","article-title":"Incidence of post-denosumab rebound hypercalcaemia in bony-metastatic breast cancer","volume":"111","author":"Wang","year":"2022","journal-title":"Calcif Tissue Int"},{"key":"2023033115541091900_","doi-asserted-by":"crossref","first-page":"3","DOI":"10.1016\/j.jclinepi.2016.07.006","article-title":"Guideline panels should seldom make good practice statements: guidance from the GRADE Working Group","volume":"80","author":"Guyatt","year":"2016","journal-title":"J Clin Epidemiol"},{"key":"2023033115541091900_","doi-asserted-by":"crossref","first-page":"161","DOI":"10.1016\/j.jclinepi.2021.09.028","article-title":"A taxonomy and framework for identifying and developing actionable statements in guidelines suggests avoiding informal recommendations","volume":"141","author":"Lotfi","year":"2022","journal-title":"J Clin Epidemiol"},{"issue":"4-5","key":"2023033115541091900_","doi-asserted-by":"crossref","first-page":"890","DOI":"10.1016\/0959-8049(92)90143-P","article-title":"Intravenous clodronate for the treatment of hypercalcaemia in breast cancer patients with bone metastases\u2013a prospective randomised placebo-controlled multicentre study","volume":"28a","author":"Rotstein","year":"1992","journal-title":"Eur J Cancer"},{"issue":"3","key":"2023033115541091900_","doi-asserted-by":"crossref","first-page":"471","DOI":"10.1001\/archinte.1991.00400030039007","article-title":"Treatment of hypercalcemia of malignancy with intravenous etidronate. A controlled, multicenter study. The Hypercalcemia Study Group","volume":"151","author":"Singer","year":"1991","journal-title":"Arch Intern Med"},{"issue":"8","key":"2023033115541091900_","doi-asserted-by":"crossref","first-page":"539","DOI":"10.1007\/s00520-003-0477-1","article-title":"Efficacy and safety of ibandronate in the treatment of hypercalcemia of malignancy: a randomized multicentric comparison to pamidronate","volume":"11","author":"Pecherstorfer","year":"2003","journal-title":"Supportive Care Cancer"},{"issue":"2","key":"2023033115541091900_","doi-asserted-by":"crossref","first-page":"558","DOI":"10.1200\/JCO.2001.19.2.558","article-title":"Zoledronic acid is superior to pamidronate in the treatment of hypercalcemia of malignancy: a pooled analysis of two randomized, controlled clinical trials","volume":"19","author":"Major","year":"2001","journal-title":"J Clin Oncol"},{"issue":"15","key":"2023033115541091900_","doi-asserted-by":"crossref","first-page":"3314","DOI":"10.1200\/JCO.2005.05.116","article-title":"Zoledronic acid significantly reduces skeletal complications compared with placebo in Japanese women with bone metastases from breast cancer: a randomized, placebo-controlled trial","volume":"23","author":"Kohno","year":"2005","journal-title":"J Clin Oncol"},{"issue":"35","key":"2023033115541091900_","doi-asserted-by":"crossref","first-page":"5132","DOI":"10.1200\/JCO.2010.29.7101","article-title":"Denosumab compared with zoledronic acid for the treatment of bone metastases in patients with advanced breast cancer: a randomized, double-blind study","volume":"28","author":"Stopeck","year":"2010","journal-title":"J Clin Oncol"},{"issue":"11","key":"2023033115541091900_","doi-asserted-by":"crossref","first-page":"1467","DOI":"10.1016\/j.ejca.2015.04.017","article-title":"The role of denosumab in the prevention of hypercalcaemia of malignancy in cancer patients with metastatic bone disease","volume":"51","author":"Diel","year":"2015","journal-title":"Eur J Cancer"},{"issue":"8","key":"2023033115541091900_","doi-asserted-by":"crossref","first-page":"756","DOI":"10.1056\/NEJMoa0809493","article-title":"Denosumab for prevention of fractures in postmenopausal women with osteoporosis","volume":"361","author":"Cummings","year":"2009","journal-title":"N Engl J Med"},{"issue":"8","key":"2023033115541091900_","doi-asserted-by":"crossref","first-page":"3246","DOI":"10.1210\/jc.2013-1814","article-title":"The endocrine society guidelines: when the confidence cart goes before the evidence horse","volume":"98","author":"Brito","year":"2013","journal-title":"J Clin Endocrinol Metab"},{"issue":"7","key":"2023033115541091900_","doi-asserted-by":"crossref","first-page":"726","DOI":"10.1016\/j.jclinepi.2013.02.003","article-title":"GRADE Guidelines: 15. Going from evidence to recommendation-determinants of a recommendation's Direction and strength","volume":"66","author":"Andrews","year":"2013","journal-title":"J Clin Epidemiol"},{"issue":"22","key":"2023033115541091900_","doi-asserted-by":"crossref","first-page":"3198","DOI":"10.1182\/bloodadvances.2018022954","article-title":"American Society of Hematology 2018 guidelines for management of venous thromboembolism: prophylaxis for hospitalized and nonhospitalized medical patients","volume":"2","author":"Sch\u00fcnemann","year":"2018","journal-title":"Blood Adv"},{"issue":"12","key":"2023033115541091900_","doi-asserted-by":"crossref","first-page":"1823","DOI":"10.1097\/JTO.0b013e31826aec2b","article-title":"Overall survival improvement in patients with lung cancer and bone metastases treated with denosumab versus zoledronic acid: subgroup analysis from a randomized phase 3 study","volume":"7","author":"Scagliotti","year":"2012","journal-title":"J Thoracic Oncol"},{"issue":"16","key":"2023033115541091900_","doi-asserted-by":"crossref","first-page":"3082","DOI":"10.1016\/j.ejca.2012.08.002","article-title":"Superiority of denosumab to zoledronic acid for prevention of skeletal-related events: a combined analysis of 3 pivotal, randomised, phase 3 trials","volume":"48","author":"Lipton","year":"2012","journal-title":"Eur J Cancer"},{"issue":"3","key":"2023033115541091900_","doi-asserted-by":"crossref","first-page":"370","DOI":"10.1016\/S1470-2045(18)30072-X","article-title":"Denosumab versus zoledronic acid in bone disease treatment of newly diagnosed multiple myeloma: an international, double-blind, double-dummy, randomised, controlled, phase 3 study","volume":"19","author":"Raje","year":"2018","journal-title":"Lancet Oncol"},{"key":"2023033115541091900_","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1080\/10428194.2022.2115840","article-title":"Denosumab versus intravenous bisphosphonate use for hypercalcemia in multiple myeloma","author":"Lei","year":"2022 29","journal-title":"Leuk Lymphoma"},{"issue":"3","key":"2023033115541091900_","doi-asserted-by":"crossref","first-page":"277","DOI":"10.1177\/1060028020957048","article-title":"Bisphosphonate versus bisphosphonate and calcitonin for the treatment of moderate to severe hypercalcemia of malignancy","volume":"55","author":"Khan","year":"2021","journal-title":"Ann Pharmacother"},{"issue":"6","key":"2023033115541091900_","doi-asserted-by":"crossref","first-page":"e207","DOI":"10.1016\/j.clml.2014.07.005","article-title":"Denosumab for the management of hypercalcemia of malignancy in patients with multiple myeloma and renal dysfunction","volume":"14","author":"Cicci","year":"2014","journal-title":"Clin Lymphoma Myeloma Leuk"},{"issue":"3","key":"2023033115541091900_","first-page":"121","article-title":"Denosumab for first-line treatment of hypercalcemia associated with malignancy: retrospective analysis","volume":"11","author":"Morgan","year":"2021","journal-title":"J Hematol Oncol Pharm"},{"issue":"7413","key":"2023033115541091900_","doi-asserted-by":"crossref","first-page":"469","DOI":"10.1136\/bmj.327.7413.469","article-title":"Systematic review of role of bisphosphonates on skeletal morbidity in metastatic cancer","volume":"327","author":"Ross","year":"2003","journal-title":"BMJ (Clinical research ed)"},{"issue":"9","key":"2023033115541091900_","doi-asserted-by":"crossref","first-page":"3144","DOI":"10.1210\/jc.2014-1001","article-title":"Denosumab for treatment of hypercalcemia of malignancy","volume":"99","author":"Hu","year":"2014","journal-title":"J Clin Endocrinol Metab"},{"issue":"2","key":"2023033115541091900_","doi-asserted-by":"crossref","first-page":"143","DOI":"10.1177\/1078155213518361","article-title":"Denosumab in hypercalcemia of malignancy: a case series","volume":"21","author":"Dietzek","year":"2015","journal-title":"J Oncol Pharm Pract"},{"issue":"2","key":"2023033115541091900_","doi-asserted-by":"crossref","first-page":"e123","DOI":"10.1016\/j.clml.2017.12.006","article-title":"Mechanisms of hypercalcemia in non-Hodgkin lymphoma and associated outcomes: A retrospective review","volume":"18","author":"Shallis","year":"2018","journal-title":"Clin Lymphoma Myeloma Leuk"},{"issue":"6","key":"2023033115541091900_","doi-asserted-by":"crossref","first-page":"1309","DOI":"10.1172\/JCI106610","article-title":"Effect of cortisone treatment on the active transport of calcium by the small intestine","volume":"50","author":"Kimberg","year":"1971","journal-title":"J Clin Invest"},{"issue":"1","key":"2023033115541091900_","doi-asserted-by":"crossref","first-page":"1","DOI":"10.7326\/0003-4819-100-1-1","article-title":"Hypercalcemia associated with increased serum calcitriol levels in three patients with lymphoma","volume":"100","author":"Breslau","year":"1984","journal-title":"Ann Intern Med"},{"issue":"5","key":"2023033115541091900_","doi-asserted-by":"crossref","first-page":"1383","DOI":"10.1182\/blood.V82.5.1383.1383","article-title":"Calcitriol: the major humoral mediator of hypercalcemia in Hodgkin's disease and non-Hodgkin's lymphomas","volume":"82","author":"Seymour","year":"1993","journal-title":"Blood"},{"issue":"17","key":"2023033115541091900_","doi-asserted-by":"crossref","first-page":"1935","DOI":"10.1001\/archinte.1994.00420170079008","article-title":"Treatment of cancer-associated hypercalcemia. Double-blind comparison of rapid and slow intravenous infusion regimens of pamidronate disodium and saline alone","volume":"154","author":"Gucalp","year":"1994","journal-title":"Arch Intern Med"},{"issue":"2a","key":"2023033115541091900_","doi-asserted-by":"crossref","first-page":"51","DOI":"10.1016\/0002-9343(87)90487-6","article-title":"Etidronate disodium in the management of malignancy-related hypercalcemia","volume":"82","author":"Hasling","year":"1987","journal-title":"Am J Med"},{"issue":"3-4","key":"2023033115541091900_","first-page":"129","article-title":"Non-Hodgkin's lymphoma and 1,25(OH)2D-related hypercalcaemia","volume":"37","author":"Craanen","year":"1990","journal-title":"Neth J Med"},{"issue":"3","key":"2023033115541091900_","doi-asserted-by":"crossref","first-page":"404","DOI":"10.1007\/BF02114405","article-title":"1,25-Dihydroxyvitamin D-related hypercalcemia in lymphoma: two case reports","volume":"9","author":"Devogelaer","year":"1990","journal-title":"Clin Rheumatol"},{"issue":"9","key":"2023033115541091900_","doi-asserted-by":"crossref","first-page":"1543","DOI":"10.1002\/1097-0142(19870501)59:9<1543::AID-CNCR2820590902>3.0.CO;2-L","article-title":"Ectopic production of 1,25-dihydroxyvitamin D by B-cell lymphoma as a cause of hypercalcemia","volume":"59","author":"Mudde","year":"1987","journal-title":"Cancer"},{"key":"2023033115541091900_","article-title":"The Parathyroids: Basic and Clinical Concepts","author":"Bilezikian","year":"2001","journal-title":"Academic Press"},{"key":"2023033115541091900_","author":"Amgen Inc","year":"2019"},{"key":"2023033115541091900_","author":"Amgen Europe B.V","year":"2022"},{"issue":"2","key":"2023033115541091900_","doi-asserted-by":"crossref","first-page":"581","DOI":"10.1210\/jc.2002-020890","article-title":"Oral alendronate increases bone mineral density in postmenopausal women with primary hyperparathyroidism","volume":"88","author":"Chow","year":"2003","journal-title":"J Clin Endocrinol Metab"},{"issue":"8","key":"2023033115541091900_","doi-asserted-by":"crossref","first-page":"2766","DOI":"10.1210\/jc.2008-2640","article-title":"Cinacalcet reduces serum calcium concentrations in patients with intractable primary hyperparathyroidism","volume":"94","author":"Marcocci","year":"2009","journal-title":"J Clin Endocrinol Metab"},{"issue":"10","key":"2023033115541091900_","doi-asserted-by":"crossref","first-page":"4482","DOI":"10.1210\/jc.2001-010385","article-title":"Alendronate in the treatment of primary hyperparathyroid-related osteoporosis: a 2-year study","volume":"87","author":"Parker","year":"2002","journal-title":"J Clin Endocrinol Metab"},{"issue":"10","key":"2023033115541091900_","doi-asserted-by":"crossref","first-page":"3803","DOI":"10.1210\/jc.2007-0585","article-title":"Cinacalcet hydrochloride reduces the serum calcium concentration in inoperable parathyroid carcinoma","volume":"92","author":"Silverberg","year":"2007","journal-title":"J Clin Endocrinol Metab"},{"issue":"6","key":"2023033115541091900_","doi-asserted-by":"crossref","first-page":"616","DOI":"10.1007\/s00774-016-0797-0","article-title":"Cinacalcet hydrochloride relieves hypercalcemia in Japanese patients with parathyroid cancer and intractable primary hyperparathyroidism","volume":"35","author":"Takeuchi","year":"2017","journal-title":"J Bone Mineral Metab"},{"issue":"10","key":"2023033115541091900_","doi-asserted-by":"crossref","first-page":"1019","DOI":"10.1530\/EC-20-0380","article-title":"Denosumab for management of severe hypercalcemia in primary hyperparathyroidism","volume":"9","author":"Eremkina","year":"2020","journal-title":"Endocr Connect"},{"issue":"5","key":"2023033115541091900_","doi-asserted-by":"crossref","first-page":"468","DOI":"10.4158\/EP14410.OR","article-title":"The emerging role of denosumab in the long-term management of parathyroid carcinoma-related refractory hypercalcemia","volume":"21","author":"Fountas","year":"2015","journal-title":"Endocr Pract"},{"issue":"2","key":"2023033115541091900_","doi-asserted-by":"crossref","first-page":"84","DOI":"10.1016\/j.jcrpr.2018.01.002","article-title":"Refractory hypercalcemia due to hyperparathyroidism in a patient with metastatic parathyroid carcinoma","volume":"5","author":"Hsu","year":"2018","journal-title":"J Cancer Res Pract"},{"issue":"1","key":"2023033115541091900_","doi-asserted-by":"crossref","first-page":"K1","DOI":"10.1530\/EJE-14-0166","article-title":"Refractory hypercalcaemia secondary to parathyroid carcinoma: response to high-dose denosumab","volume":"171","author":"Karuppiah","year":"2014","journal-title":"Eur J Endocrinol"},{"issue":"3","key":"2023033115541091900_","doi-asserted-by":"crossref","first-page":"L7","DOI":"10.1530\/EJE-14-0482","article-title":"Denosumab for management of refractory hypercalcaemia in recurrent parathyroid carcinoma","volume":"171","author":"Nadarasa","year":"2014","journal-title":"Eur J Endocrinol"},{"issue":"1","key":"2023033115541091900_","doi-asserted-by":"crossref","first-page":"49","DOI":"10.1093\/qjmed\/hcu166","article-title":"Use of denosumab in parathyroid carcinoma with refractory hypercalcemia","volume":"108","author":"Tong","year":"2015","journal-title":"QJM"},{"issue":"2","key":"2023033115541091900_","doi-asserted-by":"crossref","first-page":"387","DOI":"10.1210\/jc.2013-3031","article-title":"Denosumab for management of parathyroid carcinoma-mediated hypercalcemia","volume":"99","author":"Vellanki","year":"2014","journal-title":"J Clin Endocrinol Metab"},{"key":"2023033115541091900_","first-page":"150082","article-title":"Palliative treatment of uncontrollable hypercalcemia due to parathyrotoxicosis: denosumab as rescue therapy","volume":"2015","author":"Jumpertz von Schwartzenberg","year":"2015 29","journal-title":"Endocrinol Diabetes Metab Case Rep"},{"issue":"2","key":"2023033115541091900_","doi-asserted-by":"crossref","first-page":"e141","DOI":"10.4158\/EP14449.CR","article-title":"Denosumab for the treatment of refractory hypercalcemia in metastatic parathyroid carcinoma","volume":"1","author":"Itoshima","year":"2015","journal-title":"AACE Clin Case Rep"},{"issue":"3","key":"2023033115541091900_","doi-asserted-by":"crossref","first-page":"666","DOI":"10.1210\/jc.2007-1907","article-title":"A case for clarity, consistency, and helpfulness: state-of-the-art clinical practice guidelines in endocrinology using the grading of recommendations, assessment, development, and evaluation system","volume":"93","author":"Swiglo","year":"2008","journal-title":"J Clin Endocrinol Metab"},{"key":"2023033115541091900_","first-page":"167.e1-167.e10","article-title":"GRADE Evidence to Decision (EtD) frameworks: a systematic and transparent approach to making well informed healthcare choices. 2: Clinical practice guidelines","volume":"32(2)","author":"Alonso-Coello","year":"2018","journal-title":"Gac Sanit"},{"key":"2023033115541091900_","first-page":"166.e1-166.e10","article-title":"GRADE Evidence to Decision (EtD) frameworks: a systematic and transparent approach to making well informed healthcare choices. 1: Introduction","volume":"32(2)","author":"Alonso-Coello","year":"2018","journal-title":"Gac Sanit"},{"key":"2023033115541091900_","author":"McMaster University and Evidence Prime","year":"2020"},{"key":"2023033115541091900_","author":"Endocrine Society","year":"2019"},{"issue":"February","key":"2023033115541091900_","doi-asserted-by":"crossref","first-page":"42","DOI":"10.1016\/j.jclinepi.2020.07.022","article-title":"Supporting effective participation in health guideline development groups: the guideline participant tool","volume":"130","author":"Piggott","year":"2021","journal-title":"J Clin Epidemiol"},{"key":"2023033115541091900_","doi-asserted-by":"crossref","first-page":"106","DOI":"10.1016\/j.jclinepi.2022.01.004","article-title":"Standardized wording to improve efficiency and clarity of GRADE EtD frameworks in health guidelines","volume":"146","author":"Piggott","year":"2022","journal-title":"J Clin Epidemiol"},{"issue":"7","key":"2023033115541091900_","doi-asserted-by":"crossref","first-page":"719","DOI":"10.1016\/j.jclinepi.2012.03.013","article-title":"GRADE Guidelines: 14. Going from evidence to recommendations: the significance and presentation of recommendations","volume":"66","author":"Andrews","year":"2013","journal-title":"J Clin Epidemiol"},{"key":"2023033115541091900_","author":"Sch\u00fcnemann","year":"2013"},{"key":"2023033115541091900_","volume-title":"Common Terminology Criteria for Adverse Events (CTCAE). v.5.0 ed:","author":"U.S. Department of Health and Human Services","year":"2017"},{"key":"2023033115541091900_","volume-title":"Tietz Textbook of Clinical Chemistry and Molecular Diagnostics. JAMA","author":"Fraser","year":"2018","edition":"8th edition ed"},{"issue":"5","key":"2023033115541091900_","doi-asserted-by":"crossref","first-page":"235","DOI":"10.1177\/0885066613507530","article-title":"Hypercalcemia in the intensive care unit: a review of pathophysiology, diagnosis, and modern therapy","volume":"30","author":"Maier","year":"2015","journal-title":"J Intensive Care Med"}],"container-title":["The Journal of Clinical Endocrinology &amp; Metabolism"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/academic.oup.com\/jcem\/advance-article-pdf\/doi\/10.1210\/clinem\/dgac621\/48891719\/dgac621.pdf","content-type":"application\/pdf","content-version":"am","intended-application":"syndication"},{"URL":"https:\/\/academic.oup.com\/jcem\/article-pdf\/108\/3\/507\/49716808\/dgac621.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"syndication"},{"URL":"https:\/\/academic.oup.com\/jcem\/article-pdf\/108\/3\/507\/49716808\/dgac621.pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2023,12,3]],"date-time":"2023-12-03T06:38:48Z","timestamp":1701585528000},"score":1,"resource":{"primary":{"URL":"https:\/\/academic.oup.com\/jcem\/article\/108\/3\/507\/6916871"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2022,12,21]]},"references-count":88,"journal-issue":{"issue":"3","published-online":{"date-parts":[[2022,12,21]]},"published-print":{"date-parts":[[2023,2,15]]}},"URL":"https:\/\/doi.org\/10.1210\/clinem\/dgac621","relation":{},"ISSN":["0021-972X","1945-7197"],"issn-type":[{"value":"0021-972X","type":"print"},{"value":"1945-7197","type":"electronic"}],"subject":[],"published-other":{"date-parts":[[2023,3,1]]},"published":{"date-parts":[[2022,12,21]]}}}